CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience
Abdullah Ozkaya, Zeynep Alkin, Mesut Togac, Sibel Ahmet, Irfan Perente, Muhittin Taskapili
Korean J Ophthalmol. 2017;31(5):424-430.   Published online September 11, 2017
DOI: https://doi.org/10.3341/kjo.2016.0125

Excel Download

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience
Korean Journal of Ophthalmology. 2017;31(5):424   Crossref logo
Link1 Link2 Link3

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
Clinical Ophthalmology. 2010;1271   Crossref logo
Link1

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
Journal of Clinical Medicine. 2021;10(12):2666   Crossref logo
Link1

Visual outcome of ranibizumab therapy for neovascular age related macular degeneration in the black population: a report of five cases
Clinical Ophthalmology. 2010;913   Crossref logo
Link1

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study
Clinical Ophthalmology. 2013;1849   Crossref logo
Link1

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
Clinical Ophthalmology. 2016;1047   Crossref logo
Link1

<p>Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)</p>
Clinical Ophthalmology. 2019;Volume 13:2461-2467   Crossref logo
Link1 Link2

Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761)
Ophthalmology. 2017;124(3):e31-e32   Crossref logo
Link1 Link2

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
Clinical Ophthalmology. 2021;Volume 15:279-287   Crossref logo
Link1 Link2

Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes
Graefe's Archive for Clinical and Experimental Ophthalmology. 2014;253(8):1217-1225   Crossref logo
Link1 Link2 Link3